Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05879146 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
A Phase 2 study of Tumor, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05879146 is a Phase 2 study of Tumor that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 183-participant average among 18 other Tumor trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05879146, a Phase 2 study of Tumor, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn about the safety and effects of an investigational drug called nirogacestat when given to participants with a desmoid tumor/aggressive fibromatosis
Conditions Studied
Interventions
- DRUG Nirogacestat
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05879146
The ClinicalTrials.gov registry entry for NCT05879146 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 18 other Tumor trials with a reported enrollment target (78% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tumor appearing as the primary indexed condition, and to 1 intervention - of which Nirogacestat is the first listed.
NCT05879146 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05879146 about?
NCT05879146 is a clinical study titled "Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study". To learn about the safety and effects of an investigational drug called nirogacestat when given to participants with a desmoid tumor/aggressive fibromatosis
What is the current status of trial NCT05879146?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-11-26. Estimated completion is 2028-01-31.
What conditions does trial NCT05879146 study?
This clinical trial studies the following conditions: Tumor.
What interventions are being tested in trial NCT05879146?
The interventions under investigation include: Nirogacestat (DRUG).
Who is sponsoring clinical trial NCT05879146?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05879146 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
-
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
-
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
RECRUITING · Phase 2
-
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.